Navigation Links
Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
Date:6/19/2012

CRANBURY, N.J., June 19, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that a Phase I clinical trial being conducted by AstraZeneca of AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist under development for the treatment of obesity, has been halted. AZD2820 is a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies.

The Phase 1 clinical trial of AZD2820 was halted by the Safety Review Committee established by AstraZeneca after meeting a predefined stopping criterion. The stopping criterion was a serious adverse event. It is suspected that the subject may have had an allergic reaction following his first dose. The subject was treated at the clinical site and has fully recovered. A review and investigation of the incident has commenced.

"We are pleased that the subject has fully recovered from this unfortunate adverse event and we will work closely with our partner AstraZeneca to investigate the cause of this incident and the overall plans for the AZD2820 program," said Dr. Carl Spana, President and Chief Executive Officer of Palatin. "AstraZeneca has confirmed their remaining commitment to the continued advancement of melanocortin agonists for treatment of obesity, including a number of collaboration compounds in various stages of preclinical testing."

The phase I single center study, conducted by AstraZeneca, targeted enrolling 72 obese but otherwise healthy male subjects, with a body mass index between 30 and 35 kg/m2, in a randomized, single-blind, placebo-controlled, trial. Eleven subjects had completed their dosing regimen prior to the halting of the trial. The primary outcome of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD2820 after administration of multiple ascending doses. Another Phase 1 single ascending dose study of AZD2820 was finalize
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
2. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
3. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
4. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
5. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
6. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
7. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
8. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials
9. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
10. OrthoAccel Technologies, Inc. Names U.S. National Sales Director
11. Metamaterials, quantum dots show promise for new technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Carolina (PRWEB) April 17, 2015 ... steam system services, released their newly designed, state-of-the-art ... The customer facing website effectively promotes the Spirax ... , All the information that a site visitor ... system services, company capabilities, industries serviced, the latest ...
(Date:4/16/2015)... Capillus, LLC announces plans to expand ... Europe and Asia. The Miami-based medical device manufacturer ... Business Development Director of Svenson Group Europe, as ... professional achievements include increasing the number of Svenson ... the Portuguese marketplace with centers in Lisbon and ...
(Date:4/16/2015)... 16, 2015 According to the ... an outside source was ranked first among the ... related to lifting, pushing, pulling, holding, carrying, or ... costs. The David Round Company takes statistics like ... working hard to develop and design equipment that ...
(Date:4/16/2015)... TORONTO , April 16, 2015 /PRNewswire/ - Portage ... PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce ... Investor Show on April 25, 2015 to be held ... Dr. Gregory Bailey and Mr. James ... overview and an update on the key programs at ...
Breaking Biology Technology:Spirax Sarco website has a new look 2Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4
... Md., Feb. 15, 2011 United Therapeutics Corporation (Nasdaq: ... for the fourth quarter and year ended December 31, 2010. ... by the growth in our revenues," remarked Martine Rothblatt, ... addition, we are pleased to announce that we expect ...
... Reportlinker.com announces that a new market research report ... Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers ... http://www.reportlinker.com/p0386436/Pipeline-Insight-Cancer-Overview--Breast-and-Gynecological-Cancers---Promising-agents-emerge-for-BRCA-positive-patients.html ... types covered in this report are set to ...
... is available in French . Scientists have ... two paintings by Vincent van Gogh and other artists of ... to understanding how to stop the bright yellow colours of ... brown shade, and fading over time. In the meantime, the ...
Cached Biology Technology:United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 2United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 3United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 4United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 5United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 6United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 7United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 8United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 9Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients 2X-rays show why van Gogh paintings lose their shine 2X-rays show why van Gogh paintings lose their shine 3X-rays show why van Gogh paintings lose their shine 4
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced ... Strategic Business Report" report to their offering. This ... US$ Thousands by the following Segments: Face Biometrics, and Voice Biometrics. ... Canada , Japan , Europe ... & Africa , and ...
(Date:3/23/2015)... -- SoundView Technology Group issues a new research update following ... smart wallet. SoundView was one of the selected user groups to ... Wocket in multiple scenarios and outlets. Soundview ... making both debit and credit card payments.  ... company meets their plans in 2015, it would push our ...
(Date:3/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... television starting March 30 th . ... New York markets. ... about our new ad campaign following the recent initial shipment ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... mice has helped identify a new protein that protects sensory ... of Iowa and Kansas State University researchers. The findings appear ... PLoS Genetics . In humans, hereditary deafness is ... involved in hearing are unidentified. Mice are used as research ...
... LANSING, Mich. A Michigan State University researcher is ... food to be harmful. Norman Hord,s research suggests ... the use of nitrogen-based fertilizers and excessive nitrates in ... plants -- may actually provide health benefits. Nitrate ...
... DURHAM, N.C. The lowly appendix, long-regarded as a ... researchers at Duke University Medical Center proposed that it actually ... safe haven where good bacteria could hang out until they ... of diarrhea, for example. Now, some of ...
Cached Biology News:Research supports calls to study health benefits of nitrate, nitrite 2Evolution of the appendix: A biological 'remnant' no more 2Evolution of the appendix: A biological 'remnant' no more 3
Request Info...
PGC-1 (H-300)...
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Mouse Anti-Amyloid beta [1-16], clone 6E10, Monoclonal Antibody...
Biology Products: